High-risk prostate cancer: A disease of genomic instability

被引:26
|
作者
Tapia-Laliena, Maria A. [1 ]
Korzeniewski, Nina [1 ]
Hohenfellner, Markus [1 ]
Duensing, Stefan [1 ]
机构
[1] Heidelberg Univ, Sch Med, Dept Urol, Heidelberg, Germany
关键词
Prostate cancer; Genomic instability; Somatic mutations; DNA damage; Translational therapeutics; Biomarkers; IN-SITU HYBRIDIZATION; DNA-REPAIR; CHROMOSOME INSTABILITY; GENETIC INSTABILITY; ERG; FUSION; REARRANGEMENT; MUTATIONS; DELETIONS; CHROMOTHRIPSIS;
D O I
10.1016/j.urolonc.2014.02.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: In this review, we will discuss the latest advances in our understanding of the relationship between the cellular DNA damage response and genomic instability in prostate cancer and the emerging possibilities to exploit these aberrations as prognostic biomarkers and guides for personalized patient management. Methods: Important findings related to genomic instability in prostate cancer were retrieved from the literature and combined with our own results and a translational perspective. Results: Prostate cancer is characterized by a highly altered genomic landscape with a wide spectrum of genomic alterations, including somatic mutations, copy number alterations (CNAs), gene fusions, complex chromosomal rearrangements, and aneuploidy. In addition, massive DNA damaging events, including chromothripsis and chromoplexy, which can lead to extensive genomic insults in a single step, have been identified. A number of these genomic aberrations have been found to provide prognostic information and can therefore help to identify high-risk patients. In addition, defects in the DNA damage checkpoint and repair machinery can potentially be harnessed for therapeutic purposes. Conclusions: Genomic instability plays a crucial role in the malignant progression of prostate cancer and can be exploited for the development of novel prognostic biomarkers and innovative therapies. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:1101 / 1107
页数:7
相关论文
共 50 条
  • [11] Radiotherapy for high-risk prostate cancer
    Mohiuddin, Jahan J.
    Baker, Brock R.
    Chen, Ronald C.
    NATURE REVIEWS UROLOGY, 2015, 12 (03) : 145 - 154
  • [12] Surgery for high-risk prostate cancer
    Eden, Christopher
    TRENDS IN UROLOGY & MENS HEALTH, 2014, 5 (01) : 19 - 22
  • [13] THE RISK OF PROSTATE CANCER DEATH FOR ELDERLY MEN WITH TREATED HIGH-RISK PROSTATE CANCER AND NO OR CORRECTED CARDIOVASCULAR DISEASE
    Hoffman, Karen E.
    Chen, Ming-Hui
    Moran, Brian J.
    Braccioforte, Michelle H.
    Dosoretz, Daniel
    Salenius, Sharon
    Katin, Michael
    Ross, Rudi
    D'Amico, Anthony V.
    JOURNAL OF UROLOGY, 2009, 181 (04): : 207 - 207
  • [14] Genomic alterations in intraductal prostate cancer: Insights from the Genomic Umbrella Neoadjuvant study (GUNS) in high-risk localized disease.
    Bernardino, Rui
    Scurll, Joshua
    Oo, Htoo Zarni
    Nappi, Lucia
    Wyatt, Alexander William
    Zoubeidi, Amina
    Berlin, Doron
    Sildva, Tiiu
    Cockburn, Jessica Grace
    van der Kwast, Theodorus
    Gleave, Martin
    Fleshner, Neil Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [15] Surgery for high-risk prostate cancer and metastatic prostate cancer
    Safir, Ilan J.
    Lian, Fei
    Alemozaffar, Mehrdad
    Master, Viraj A.
    CURRENT PROBLEMS IN CANCER, 2015, 39 (01) : 33 - 40
  • [16] Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer
    Muralidhar, Vinayak
    Zhang, Jingbin
    Wang, Qiqi
    Mahal, Brandon A.
    Butler, Santino S.
    Spratt, Daniel E.
    Davicioni, Elai
    Sartor, Oliver
    Feng, Felix Y.
    Mouw, Kent W.
    Nguyen, Paul L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (03): : 621 - 627
  • [17] A genomic classifier independently prognostic of prostate cancer death in a high-risk surgical cohort
    Cooperberg, Matthew R.
    Crisan, Anamaria
    Mitra, Anirban Pradip
    Ghadessi, Mercedeh
    Buerki, Christine
    Davicioni, Elai
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [18] Intratumoural (IT) evolutionary landscape of high-risk prostate cancer and outcome: The PROGENY (PROstate cancer GENomic heterogeneitY) study of genomic and immune parameters.
    Jayaram, Anuradha
    Goh, Gerald
    Kularatne, Bihani Yoshana
    Waterhouse, Jasmin
    Shanmugabavan, Yaalini
    Rowan, Andrew
    Wong, Yien Ning Sophia
    Freeman, Alex
    Akarca, Ayse
    Herrero, Javier
    Rosenthal, Rachel
    McGranahan, Nicholas
    Hung, Michelle
    Emberton, Mark
    Attard, Gerhardt
    Quezada, Sergio A.
    Marafioti, Teresa
    Ahmed, Hashim Uddin
    Swanton, Charles
    Linch, Mark David
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [19] High-risk prostate cancer: How high is high?
    Sandler, HM
    CANCER JOURNAL, 2002, 8 (04): : 301 - 302
  • [20] Molecular Imaging of Primary Prostate Cancer Identifies High-Risk Disease
    Piert, M. R.
    Park, H.
    Khan, A.
    Hussain, H.
    Meyer, C.
    Shah, R.
    Wood, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S156 - S156